Bio-Rad Laboratories (BIO) vs Pacific Biosciences of California (PACB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Pacific Biosciences of California (PACB) has outperformed Bio-Rad Laboratories (BIO) over the past year, gaining 94.3% versus a gain of 24.1%. Over five years, BIO leads with a -49.0% price change compared with -88.8% for PACB. Bio-Rad Laboratories is the larger company by market cap ($9.84 billion vs $845.5 million), about 11.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIO | PACB |
|---|---|---|
| Share price | $367.92 | $2.72 |
| Market cap | $9.84B | $845.46M |
| 1-day change | -0.25% | +0.74% |
| YTD return | +21.43% | +45.45% |
| 1-year return | +24.08% | +94.29% |
| 5-year return | -49.00% | -88.85% |
| P/E ratio (TTM) | 46.63 | — |
| Forward P/E | 37.10 | — |
| EPS (TTM) | $7.89 | $-0.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.58B | — |
| Revenue growth (YoY) | +0.65% | — |
| Net income (latest FY) | $759.90M | — |
| Gross margin | 51.87% | — |
| Operating margin | 1.83% | — |
| Net margin | 29.42% | — |
| 52-week high | $396.23 | $3.44 |
| 52-week low | $236.73 | $1.07 |
| Distance from 52-week high | -7.14% | -20.93% |
| Analyst consensus | hold | buy |
| Avg. price target upside | -10.76% | -20.59% |
| Average volume | 276.93K | 10.10M |
| Shares outstanding | 21.68M | 310.83M |
| Employees | 7,450 | 485 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Bio-Rad Laboratories is about 11.6 times larger than Pacific Biosciences of California by market value ($9.84B vs $845.46M).
- PACB has outperformed BIO by 70.2 percentage points over the past year.
About Bio-Rad Laboratories
BIO stock →Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally.
Industrials · Biotechnology: Laboratory Analytical Instruments · 7,450 employees
About Pacific Biosciences of California
PACB stock →Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems.
Industrials · Biotechnology: Laboratory Analytical Instruments · 485 employees
BIO vs PACB FAQ
Which is bigger, Bio-Rad Laboratories or Pacific Biosciences of California?
Bio-Rad Laboratories (BIO) is larger, with a market capitalization of $9.84B compared with $845.46M for Pacific Biosciences of California (PACB).
Which stock has performed better over the past year, BIO or PACB?
PACB returned +94.29% over the past 12 months, compared with +24.08% for BIO (price return, excluding dividends). Past performance does not predict future results.
Are Bio-Rad Laboratories and Pacific Biosciences of California in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.